Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$7.435
−$0.195 · -2.56%
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Regular session
$7.435
−$0.195 · -2.56%
Regular session · ET · Market data may be delayed.
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Day range
Current $7.435
52-week range
Current $7.435
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
43
Mixed
Risk
76
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Day range
Current $7.435
52-week range
Current $7.435
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 392.74K USD | 745.59K USD | 769.69K USD | 604.4K USD | 26.46K USD |
| Gross profit | −392.74K USD | −745.59K USD | −769.69K USD | −604.4K USD | −26.46K USD |
| Research and development | 948.29K USD | 1.07M USD | 1.58M USD | 2.51M USD | 438.32K USD |
| Selling, general, and administrative | 2.43M USD | 2.92M USD | 4.69M USD | 5.11M USD | 943.04K USD |
| Operating expenses | 3.38M USD | 3.99M USD | 6.27M USD | 7.62M USD | 1.38M USD |
| Depreciation and amortization | 392.74K USD | 745.59K USD | 769.69K USD | 604.4K USD | 26.46K USD |
| Operating income | −3.77M USD | −4.74M USD | −6.27M USD | −7.62M USD | −1.38M USD |
| Net income | −3.58M USD | −4.3M USD | −5.87M USD | −7.42M USD | −1.35M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Cash distributions grouped by calendar year; partial years are marked.
$0.88
2017 complete year+4.8% since 2013
$0.84
2,013
$0.88
2,014
$0.88
2,015
$0.88
2,016
$0.88
2,017
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Feb 15, 2018 | $8.36Quarterly | — | Feb 26, 2018 |
Dividend | Dec 1, 2017 | $8.36Quarterly | — | Dec 15, 2017 |
Dividend | Aug 31, 2017 | $8.36Quarterly | — | Sep 15, 2017 |
Dividend | Jun 1, 2017 | $8.36Quarterly | — | Jun 15, 2017 |
Dividend | Mar 1, 2017 | $8.36Quarterly | — | Mar 15, 2017 |
Dividend | Dec 1, 2016 | $8.36Quarterly | — | Dec 15, 2016 |
Ex-dividend Feb 15, 2018
$8.36
Quarterly
Payment Feb 26, 2018
Ex-dividend Dec 1, 2017
$8.36
Quarterly
Payment Dec 15, 2017
Ex-dividend Aug 31, 2017
$8.36
Quarterly
Payment Sep 15, 2017
Ex-dividend Jun 1, 2017
$8.36
Quarterly
Payment Jun 15, 2017
Ex-dividend Mar 1, 2017
$8.36
Quarterly
Payment Mar 15, 2017
Ex-dividend Dec 1, 2016
$8.36
Quarterly
Payment Dec 15, 2016
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
